Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74204c03f11e804562771b3f1635bb0e |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate |
2018-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32c198cc705c66772ed5dc77a4460814 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_015103d114a942a477bcf4a6c1463de7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c245c154ceb187d981c6c232d7075905 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0830c64c2fd9af78e6017cd1825d29cc |
publicationDate |
2020-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
BR-112020012250-A2 |
titleOfInvention |
anticancer combination therapy with an iap antagonist and anti pd-1 molecule |
abstract |
the present invention relates to the use of an iap antagonist for pretreating a human individual diagnosed with cancer to increase the likelihood that subsequent treatment with an anti-pd-1 molecule will result in an anticancer response or to increase the responsiveness of the individual's cancer to subsequent treatment with the anti-pd-1 molecule. likewise covered are methods of treating an individual's cancer, methods comprising pretreating the individual with an iap antagonist and the subsequent treatment of the individual with an anti-pd-1 molecule. |
priorityDate |
2017-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |